Pliant Therapeutics (PLRX) Stifel 2024 Healthcare Conference summary

Pipeline and clinical development progress

• Lead asset bexotegrast targets integrins αvβ6 and αvβ1, key drivers of fibrosis in IPF and liver disease.

• Phase II-A trial showed dose-dependent efficacy, stabilization of fibrosis, and favorable safety out to 40 weeks.

• Seamless phase II-B/III BEACON-IPF trial is enrolling globally, with full enrollment expected in Q1 and topline data mid-2026.

• FDA has encouraged pivotal design for phase II-B; phase III U.S. expansion may follow additional safety data.

• Safety profile remains strong, with over 700 patients dosed and no exacerbations observed.

Market landscape and unmet needs

• Current IPF therapies slow disease but have significant tolerability issues, leading to under-treatment of about half of diagnosed patients.

• Market size is approximately $4 billion, with a major opportunity for therapies with improved tolerability and equivalent efficacy.

• Recent clinical failures in the space highlight the importance of robust, predictive phase II designs.

• New PDE4 inhibitor from BI met its phase III endpoint, validating rigorous development approaches.

Expansion opportunities and regulatory strategy

• Bexotegrast is being considered for progressive pulmonary fibrosis (PPF), with similar pathophysiology and regulatory path as IPF.

• PSC (liver fibrosis) program showed promising phase II data, but regulatory uncertainty has paused further development in favor of IPF/PPF.

• Oncology (αvβ8/αvβ1 inhibitor) and DMD (α7β1 agonist) programs are in early stages, with partnership discussions anticipated after more data.